Israeli generics giant Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2024.
2024 revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023, said Teva, whose shares were down 7.1% at 7,395 shekels following the announcement. as the company's 2025 outlook came in below expectations.
The company expects earnings per share of $2.35-$2.65 this year, below the $2.78 consensus. It projects 2025 revenue of $16.8-17.4 billion, compared to analyst estimates of $17.09 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze